AbbVie Guides Q3 EPS Below Consensus on $216M IPR&D Charge
ABBV sits 39% above its 52-week low of $190.75.
Summary
AbbVie disclosed in an SEC filing that Q3 2026 GAAP and adjusted earnings include a $216 million bought IPR&D and milestones expense, reducing diluted EPS by $0.11. The company guided Q3 adjusted diluted EPS to $3.73-$3.77, below the LSEG consensus of $3.84. Full-year 2026 adjusted EPS guidance including the charge is $13.76-$13.96, also below the $14.02 consensus. This is the first disclosure of these specific figures and the IPR&D impact, providing new information on near-term earnings pressure.
At the time of this announcement, ABBV was trading at $265.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $469.6B. The 52-week trading range was $190.75 to $269.39. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.